Presbyopia correction is widely considered one of the unmet needs of refractive cataract surgery, particularly at the corneal plane, but cornea-based methods may be viable alternatives to more entrenched lens-based approaches, according to some experts…
The Many Facets of Dacryoadenitis
What are the common causes of lacrimal gland inflammation and how is it best managed? A new review discusses the etiology and treatment options. Current Opinion in Ophthalmology
Corvis ST tonometer yields reliable IOP, central corneal thickness readings
A new non-contact tonometer provided accurate IOP and central corneal thickness measurements but less accurate corneal deformation measurements, according to a study.The Corvis ST (Oculus), an automated non-contact air-puff tonometer with ultra-high-sp…
CMS, ONC issue new rules to make EHR better accessed, more useful
HHS has issued new rules to the Electronic Heath Record Incentive Program and the Health IT Certification Program that will make EHR information more available to patients, simplify information sharing and ease the burden on health care providers, according to a press release. “We have a shared goal of electronic health records helping physicians, clinicians and hospitals to deliver better care, smarter spending and healthier people. We eliminated unnecessary requirements, simplified and increased flexibility for those that remain, and focused on interoperability, information exchange, and patient engagement. By 2018, these rules move us beyond the staged approach of ‘meaningful use’ and focus on broader delivery system reform,” Patrick Conway MD, MSc, CMS deputy administrator for innovation and quality and chief medical officer, said in a press release.
Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting’s Retina Subspecialty Day. In July, the company announced data showing that a combination of AKB-9778 and Lucentis® provided significa
Seeing in a new light
An animal’s ability to perceive light incorporates many complex processes. Now, researchers in Craig Montell’s lab at UC Santa Barbara have used fruit flies and mice to make novel discoveries about…